このエピソードについて
Rare neurological diseases present unique challenges for clinical development, where progress is often limited not only by scientific complexity, but by gaps in meaningful, high-quality data. In this episode of Cortex Conversations, experts explore how aligning regulatory expectations with real-world patient and caregiver needs can help overcome these barriers.
The discussion examines the critical role of natural history data in supporting external control arms and alternative trial designs, while also addressing the burden traditional site-based trials can place on patients—particularly in pediatric and neurodegenerative conditions. Participants share perspectives on emerging hybrid and decentralized approaches, the growing value of patient-driven data, and the collaborative efforts required to build natural history datasets that are both scientifically robust and practical for rare disease communities.
Together, the conversation highlights a path forward for advancing research in rare neurological diseases through innovation, partnership, and patient-centered trial design.
The discussion examines the critical role of natural history data in supporting external control arms and alternative trial designs, while also addressing the burden traditional site-based trials can place on patients—particularly in pediatric and neurodegenerative conditions. Participants share perspectives on emerging hybrid and decentralized approaches, the growing value of patient-driven data, and the collaborative efforts required to build natural history datasets that are both scientifically robust and practical for rare disease communities.
Together, the conversation highlights a path forward for advancing research in rare neurological diseases through innovation, partnership, and patient-centered trial design.
英語
アメリカ合衆国
文字起こし 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
このポッドキャストの他のエピソード
Host: Amber Burg, Therapeutic Delivery Head of Neuroscience and Ophthalmology at Fortrea
Participants:
Leone Atkinson, Executive Medical Director of Neuroscience and Ophthalmology at Fortrea
Alicia Baker, Vice President, Head of Global Regulatory Strategy at Fortrea
Description: Digital endpoints …
Join Leone Atkinson, Fortrea’s Executive Medical Director of Neuroscience and Ophthalmology, and Dr. John Huffaker from the Neuropsychiatric Research Center as they discuss the evolving landscape of Alzheimer’s clinical trials. Explore challenges in patient recruitment and retention, the role of ca…
Host: Amber Burg, Therapeutic Delivery Head of Neuroscience and Ophthalmology at Fortrea
Participants:
Leone Atkinson, Executive Medical Director of Neuroscience and Ophthalmology, Fortrea
Robin Wolz, Chief Scientific Officer at Ixico
Description: This episode features an insightful interview bet…
Host: Amber Burg, Therapeutic Delivery Head of Neuroscience and Ophthalmology at Fortrea
Participants:
Joanie Brown, Head of Operations at our Rapid Development Studio AI/ML, Fortrea
Mark Austin, Chief Technology Officer at Ixico
Description: In this episode of the Fortrea neuroscience podcast, w…
Host: Amber Burg, Therapeutic Delivery Head of Neuroscience and Ophthalmology at Fortrea
Participants:
Abby Fuller, Senior Director of Strategic Delivery Growth in Neuroscience, Fortrea
Walter Gonzalez, Associate Director, Digital Health and Innovation, Fortrea
Haiyan Wei, SVP of Technology and O…
免責: このページに埋め込まれているポッドキャストとアートワークは Fortrea からのものであり、その所有者の所有物であり、Listen Notes, Inc. と提携または承認されていません。